Navigation Links
iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
Date:9/30/2010

SOUTH SAN FRANCISCO, Calif., Sept. 30 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that it has appointed Michael P. Smith as Vice President, Business Development and Wayne Montgomery, J.D.,  as Vice President, Legal Affairs and Intellectual Property.

"Mike brings to iPierian a breadth of strategic and transactional experience at both small and large companies.  This will be invaluable as we enter therapeutic drug discovery collaborations with global biopharma companies, to achieve our goal of using iPSC technology to transform drug discovery and development," said Michael C. Venuti, Ph.D., CEO of iPierian.  "Wayne has built and executed IP strategies spanning broad technology platforms to small molecule compositions.  As we advance our foundational intellectual property for iPSC drug discovery, as well as move our lead therapeutic programs forward, his leadership will be a key part of creating value for iPierian. We are delighted to welcome these two executives with such strong experience and track records."

Michael Smith most recently served as Head of Business Development and Chief Financial Officer for Memory Pharmaceuticals, which was acquired by Roche.  His experience includes a broad range of strategic transactions and initiatives including product and technology licenses, R&D collaborations, joint ventures, M&A, and strategic and portfolio planning.  Prior to Memory, Mr. Smith served as Vice President of Business Development for QLT Inc., where he was responsible for all business development activities and corporate strategy.  From 1998 to 2004, he was with Chiron Corporation most recently as Director of Corporate Development and held positions in several functions including strategic planning, corporate finance and commercial sales.  Mr. Smith holds a B.S. from the University of Virginia and an M.B.A. from the University of California, Berkeley.

Wayne Montgomery, J.D., joins iPierian with over twenty years of experience as an intellectual property law attorney in the biopharmaceutical industry.  He most recently served as Vice President of Patents at Exelixis.  Previously, he served as Vice President of Intellectual Property at Nektar Therapeutics.  He held the position of Vice President, Assistant General Counsel & Chief Patent Counsel at Axys Pharmaceuticals prior to its acquisition by Celera, and subsequently Vice President of Intellectual Property at Celera Genomics.  Mr. Montgomery began his legal career with Syntex Legal Affairs.  Prior to entering the legal profession, he served as a pharmacologist with Syntex Research.  He received a J.D. degree from Santa Clara University School of Law and undergraduate degrees in biochemistry and pharmacology from the University of California, Santa Barbara.

About iPierian

iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute and The University of California, San Francisco.  Our scientific founders are George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, and Deepak Srivastava, M.D., of the Gladstone Institute and UCSF.

iPierian is located in South San Francisco, California. For more information, please visit www.ipierian.com.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
2. iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming
3. iPierian to Collaborate With Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant
4. iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer
5. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
6. Vital Therapies Expands SILVER Trial to Saudi Arabia
7. Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs
8. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
9. Advanced Life Sciences Expands Antibiotic Pipeline
10. London Genetics Expands its Senior Advisory Team
11. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):